
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial
- Author
- Els Tobback (UGent) , Sophie Degroote (UGent) , Sabine Buysse, Liesbeth Delesie (UGent) , Lucas Van Dooren, Sophie Vanherrewege (UGent) , Cyril Barbezange, Veronik Hutse, Marta Romano, Isabelle Thomas, Elizaveta Padalko, Steven Callens (UGent) and Marie-Angélique De Scheerder (UGent)
- Organization
- Abstract
- Objectives: This study aimed to assess the efficacy and safety of 300 mg camostat mesylate three times daily in a fasted state to treat early phase COVID-19 in an ambulatory setting. Methods: We conducted a phase II randomized controlled trial in symptomatic (maximum 5 days) and asymptomatic patients with confirmed COVID-19 infection. Patients were randomly assigned in a 2:1 ratio to receive either camostat mesylate or a placebo. Outcomes included change in nasopharyngeal viral load, time to clinical improvement, the presence of neutralizing antibodies, and safety. Results: Of 96 participants randomized between November 2020 and June 2021, analyses were performed on the data of 90 participants who completed treatment (N = 61 camostat mesylate, N = 29 placebo). The estimated mean change in cycle threshold between day 1 and day 5 between the camostat and placebo group was 1.183 (P = 0.511). The unadjusted hazard ratio for clinical improvement in the camostat group was 0.965 (95% confidence interval, 0.480-1.942, P = 0.921 by Cox regression). The percentage distribution of the 50% neutralizing antibody titer at day 28 visit and frequency of adverse events were similar between the two groups. Conclusion: Under this protocol, camostat mesylate was not found to be effective as an antiviral drug against SARS-CoV-2.
- Keywords
- General Medicine, Camostat, COVID-19, Efficacy, Neutralizing antibodies, Randomized controlled trial, Safety
Downloads
-
1-s2.0-S1201971222003885-main.pdf
- full text
- |
- open access
- |
- |
- 1.12 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01H8E5A7HTPXMWMF34R370M94G
- MLA
- Tobback, Els, et al. “Efficacy and Safety of Camostat Mesylate in Early COVID-19 Disease in an Ambulatory Setting : A Randomized Placebo-Controlled Phase II Trial.” INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol. 122, 2022, pp. 628–35, doi:10.1016/j.ijid.2022.06.054.
- APA
- Tobback, E., Degroote, S., Buysse, S., Delesie, L., Van Dooren, L., Vanherrewege, S., … De Scheerder, M.-A. (2022). Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 122, 628–635. https://doi.org/10.1016/j.ijid.2022.06.054
- Chicago author-date
- Tobback, Els, Sophie Degroote, Sabine Buysse, Liesbeth Delesie, Lucas Van Dooren, Sophie Vanherrewege, Cyril Barbezange, et al. 2022. “Efficacy and Safety of Camostat Mesylate in Early COVID-19 Disease in an Ambulatory Setting : A Randomized Placebo-Controlled Phase II Trial.” INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 122: 628–35. https://doi.org/10.1016/j.ijid.2022.06.054.
- Chicago author-date (all authors)
- Tobback, Els, Sophie Degroote, Sabine Buysse, Liesbeth Delesie, Lucas Van Dooren, Sophie Vanherrewege, Cyril Barbezange, Veronik Hutse, Marta Romano, Isabelle Thomas, Elizaveta Padalko, Steven Callens, and Marie-Angélique De Scheerder. 2022. “Efficacy and Safety of Camostat Mesylate in Early COVID-19 Disease in an Ambulatory Setting : A Randomized Placebo-Controlled Phase II Trial.” INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 122: 628–635. doi:10.1016/j.ijid.2022.06.054.
- Vancouver
- 1.Tobback E, Degroote S, Buysse S, Delesie L, Van Dooren L, Vanherrewege S, et al. Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2022;122:628–35.
- IEEE
- [1]E. Tobback et al., “Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial,” INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol. 122, pp. 628–635, 2022.
@article{01H8E5A7HTPXMWMF34R370M94G, abstract = {{Objectives: This study aimed to assess the efficacy and safety of 300 mg camostat mesylate three times daily in a fasted state to treat early phase COVID-19 in an ambulatory setting. Methods: We conducted a phase II randomized controlled trial in symptomatic (maximum 5 days) and asymptomatic patients with confirmed COVID-19 infection. Patients were randomly assigned in a 2:1 ratio to receive either camostat mesylate or a placebo. Outcomes included change in nasopharyngeal viral load, time to clinical improvement, the presence of neutralizing antibodies, and safety. Results: Of 96 participants randomized between November 2020 and June 2021, analyses were performed on the data of 90 participants who completed treatment (N = 61 camostat mesylate, N = 29 placebo). The estimated mean change in cycle threshold between day 1 and day 5 between the camostat and placebo group was 1.183 (P = 0.511). The unadjusted hazard ratio for clinical improvement in the camostat group was 0.965 (95% confidence interval, 0.480-1.942, P = 0.921 by Cox regression). The percentage distribution of the 50% neutralizing antibody titer at day 28 visit and frequency of adverse events were similar between the two groups. Conclusion: Under this protocol, camostat mesylate was not found to be effective as an antiviral drug against SARS-CoV-2.}}, author = {{Tobback, Els and Degroote, Sophie and Buysse, Sabine and Delesie, Liesbeth and Van Dooren, Lucas and Vanherrewege, Sophie and Barbezange, Cyril and Hutse, Veronik and Romano, Marta and Thomas, Isabelle and Padalko, Elizaveta and Callens, Steven and De Scheerder, Marie-Angélique}}, issn = {{1201-9712}}, journal = {{INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES}}, keywords = {{General Medicine,Camostat,COVID-19,Efficacy,Neutralizing antibodies,Randomized controlled trial,Safety}}, language = {{eng}}, pages = {{628--635}}, title = {{Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial}}, url = {{http://doi.org/10.1016/j.ijid.2022.06.054}}, volume = {{122}}, year = {{2022}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: